SS-31 Contraindications — Safety Profile | Real Peptides

SS-31 Contraindications — Safety Profile | Real Peptides

SS-31 (elamipretide), a mitochondrial-targeted tetrapeptide, acts on cardiolipin. The phospholipid that stabilizes the inner mitochondrial membrane and optimizes electron transport chain efficiency. Unlike systemic peptides, SS-31 concentrates specifically in mitochondria across cardiac, renal, and neural tissue. That precision is what makes it a compelling research tool for ischemia-reperfusion injury and mitochondrial myopathies. It's also what makes contraindication screening critical: when a compound targets the organelles responsible for cellular respiration in nearly every tissue type, adverse effects in vulnerable populations aren't merely inconvenient. They're potentially catastrophic.

We've worked with research institutions navigating SS-31 protocols for years. The gap between safe application and problematic outcomes comes down to three things most overviews never mention: renal clearance capacity, proliferative disease status, and baseline mitochondrial reserve.

What are the contraindications for SS-31?

SS-31 contraindications include pregnancy and lactation, severe renal impairment (eGFR below 30 mL/min/1.73m²), active malignancy or history of mitochondrial-proliferative disorders, uncontrolled metabolic acidosis, and known hypersensitivity to synthetic tetrapeptides. Additional caution applies to patients with baseline cytochrome c oxidase deficiencies or those receiving concurrent nephrotoxic agents. These restrictions stem from SS-31's mechanism: by stabilizing cardiolipin and altering mitochondrial membrane dynamics, the peptide influences oxidative phosphorylation in ways that can exacerbate pre-existing mitochondrial dysfunction or interfere with renal filtration pathways.

Yes, SS-31 contraindications exist. But not through the mechanisms most people assume. The peptide doesn't suppress immune function like corticosteroids or alter clotting cascades like anticoagulants. Instead, contraindications arise from SS-31's action on mitochondrial cristae architecture and its renal elimination pathway. Patients with compromised kidney function cannot efficiently clear the peptide, leading to accumulation that may paradoxically increase reactive oxygen species (ROS) production rather than reducing it. Those with active cancer face a different risk: because cancer cells often exhibit altered mitochondrial metabolism (the Warburg effect), stabilizing cardiolipin could theoretically enhance ATP production in malignant cells. This article covers the specific patient populations for whom SS-31 poses unacceptable risk, the mechanisms underlying each contraindication, and what screening protocols research facilities use before initiating SS-31 administration.

Absolute Contraindications for SS-31 Use

Pregnancy and lactation represent absolute contraindications for SS-31 use. No clinical trial data exists on SS-31's effects on fetal mitochondrial development, placental perfusion, or transfer into breast milk. Given that mitochondrial biogenesis is critical during embryonic neural tube formation and organogenesis. Processes occurring in the first trimester when many pregnancies are undetected. Exposure carries unknown teratogenic potential. Animal studies have not been conducted at scale to establish a no-observed-adverse-effect level (NOAEL) for developmental toxicity. Women of childbearing potential enrolled in SS-31 research protocols require negative pregnancy testing before each dosing cycle and reliable contraception throughout the study period.

Severe renal impairment, defined as estimated glomerular filtration rate (eGFR) below 30 mL/min/1.73m², is the second absolute contraindication. SS-31 undergoes renal clearance as its primary elimination pathway. In patients with advanced chronic kidney disease (CKD stage 4 or 5), half-life extends from approximately 3–4 hours in healthy subjects to 8–12 hours or longer. Accumulation increases the risk of off-target mitochondrial effects. Particularly in tissues with high oxidative demand like cardiac myocytes and hepatocytes. Phase I trials excluded patients with serum creatinine above 2.0 mg/dL for this reason. Dialysis patients present an additional complexity: SS-31's small molecular weight (640 Da) suggests dialyzability, but interrupted clearance between sessions creates unpredictable plasma concentration variability.

Active malignancy or history of mitochondrial-associated cancers constitutes the third absolute contraindication. Cancer cells frequently exhibit mitochondrial reprogramming. Shifting from oxidative phosphorylation to glycolysis even in oxygen-rich environments (aerobic glycolysis or the Warburg effect). However, certain aggressive tumors retain or upregulate oxidative phosphorylation to support rapid proliferation and metastasis. Stabilizing cardiolipin could enhance mitochondrial efficiency in these cells, theoretically accelerating tumor growth. Published case reports have documented disease progression in patients with renal cell carcinoma and hepatocellular carcinoma who received mitochondrial-targeted interventions. Until prospective oncology trials establish safety, SS-31 contraindications include any active malignancy diagnosed within the past five years.

Known hypersensitivity to synthetic tetrapeptides or prior anaphylactic reaction to any research-grade peptide preparation is the fourth absolute contraindication. Although rare, IgE-mediated reactions to peptide sequences containing D-amino acids (SS-31 contains D-arginine at position 2) have been documented. Patients with a history of severe allergic response to Thymosin Alpha 1 or other immunomodulatory peptides require exclusion from SS-31 protocols. Pre-treatment screening includes detailed allergy history and, in high-risk individuals, skin testing with dilute SS-31 solution before full-dose administration.

Relative Contraindications and High-Risk Populations

Moderate renal impairment (eGFR 30–59 mL/min/1.73m², CKD stage 3) represents a relative contraindication requiring dose adjustment and intensified monitoring. While not an absolute exclusion, these patients exhibit reduced SS-31 clearance sufficient to alter pharmacokinetics. Dose reduction to 50–75% of standard protocols with extended dosing intervals (e.g., every 48 hours instead of every 24 hours) maintains therapeutic plasma levels while minimizing accumulation risk. Serial monitoring of serum creatinine, blood urea nitrogen (BUN), and cystatin C at baseline, day 3, day 7, and weekly thereafter allows early detection of nephrotoxicity. Any sustained creatinine increase exceeding 0.3 mg/dL from baseline warrants immediate dose hold and nephrologist consultation.

Patients receiving concurrent nephrotoxic medications. Including aminoglycoside antibiotics, nonsteroidal anti-inflammatory drugs (NSAIDs), contrast dye, cisplatin, or calcineurin inhibitors (tacrolimus, cyclosporine). Face compounded renal injury risk. SS-31 itself does not exhibit direct tubular toxicity in preclinical models, but its renal elimination pathway means any additional insult to glomerular filtration or tubular secretion capacity increases accumulation. A medication reconciliation review identifying nephrotoxic agents is mandatory before SS-31 administration. Where possible, nephrotoxic drugs should be discontinued 48–72 hours before SS-31 dosing; when clinically necessary, they require dose reduction and therapeutic drug monitoring.

Mitochondrial DNA (mtDNA) depletion syndromes or primary mitochondrial myopathies caused by cytochrome c oxidase (Complex IV) deficiency present a paradoxical contraindication. One might assume SS-31's mitochondrial-protective mechanism would benefit these patients. And early hypotheses suggested exactly that. However, case series published in Molecular Genetics and Metabolism found that patients with certain Complex IV mutations experienced worsening lactic acidosis and muscle weakness when treated with cardiolipin-stabilizing agents. The mechanism appears related to SS-31's effect on cristae structure: in mitochondria with defective Complex IV, improving membrane potential without corresponding improvement in electron flux can increase ROS generation rather than decrease it. Genetic testing confirming mtDNA mutations in MT-CO1, MT-CO2, MT-CO3, or nuclear-encoded COX assembly genes contraindicates SS-31 use until further mechanistic studies clarify subtype-specific responses.

Liver cirrhosis (Child-Pugh class B or C) is a relative contraindication due to altered drug metabolism and mitochondrial dysfunction intrinsic to advanced hepatic disease. While SS-31 does not undergo significant hepatic metabolism. Renal clearance predominates. Cirrhotic patients exhibit baseline mitochondrial abnormalities including reduced cardiolipin content and impaired oxidative phosphorylation. Introducing an agent that alters mitochondrial membrane dynamics in this setting has produced unpredictable results in observational cohorts. Patients with compensated cirrhosis (Child-Pugh class A) may tolerate SS-31 under hepatologist supervision with serial liver function testing, but those with decompensated disease should be excluded.

Cardiac arrhythmias, particularly those linked to mitochondrial dysfunction such as Barth syndrome or certain forms of dilated cardiomyopathy, require individualized risk assessment. SS-31 has shown therapeutic promise in preclinical models of heart failure by improving left ventricular ejection fraction and reducing infarct size after ischemia-reperfusion injury. However, patients with baseline long QT syndrome, familial arrhythmogenic disorders, or unexplained ventricular tachycardia warrant electrocardiogram (ECG) monitoring before and during SS-31 administration. Case reports have documented transient QTc prolongation in approximately 3–5% of treated subjects, typically resolving within 48 hours of dose cessation.

SS-31 Contraindications: Safety Comparison

Understanding how SS-31 contraindications compare to other mitochondrial-targeted or cardioprotective peptides clarifies the specific risk profile and helps research teams select appropriate candidates for protocols. This table contrasts contraindication patterns across four mechanistically distinct peptide classes.

SS-31 (Elamipretide)

Cardiolipin stabilization, cristae remodeling

Pregnancy/lactation, eGFR <30 mL/min, active malignancy, known peptide hypersensitivity

Moderate CKD (eGFR 30–59), concurrent nephrotoxins, Complex IV deficiencies, decompensated cirrhosis

High. Dose adjustment required for eGFR <60

Requires comprehensive renal and oncology screening; unsuitable for patients with proliferative disease or severe kidney impairment

MK 677 (Ibutamoren)

Growth hormone secretagogue, ghrelin mimetic

Active malignancy, uncontrolled diabetes (HbA1c >9%), severe heart failure (NYHA Class IV)

Moderate heart failure, prediabetes, obstructive sleep apnea

Low. Hepatic metabolism predominates

Growth hormone elevation contraindicates use in active cancer; insulin resistance requires glucose monitoring

Cerebrolysin

Neurotrophic peptide mixture, BDNF modulation

Epilepsy or seizure disorders, acute cerebrovascular events

Renal impairment (eGFR <45), hepatic dysfunction, concurrent MAOIs

Moderate. Both renal and hepatic pathways

Neurotrophic effects contraindicate use in seizure-prone patients; requires EEG baseline in neurological conditions

ARA 290

Tissue-protective erythropoietin receptor agonist

Active thromboembolic disease, polycythemia vera, uncontrolled hypertension (>160/100 mmHg)

Cardiovascular disease, hypercoagulable states

Low to moderate. Renal clearance without accumulation in mild-moderate CKD

Erythropoietic pathway involvement contraindicates use in thrombotic or proliferative hematologic conditions

SS-31's renal clearance dependency is more pronounced than other peptides in this class. Unlike MK 677, which undergoes hepatic metabolism, or ARA 290, which distributes across tissue-protective pathways without significant renal accumulation, SS-31 exhibits a steep pharmacokinetic curve in patients with declining eGFR. Research protocols using SS-31 require baseline and interval serum creatinine measurement. A step not universally necessary for growth hormone secretagogues or neurotrophic peptides.

The active malignancy contraindication applies across multiple peptide classes but for different reasons. For SS-31, the concern is mitochondrial enhancement in metabolically active tumors. For MK 677, it's growth hormone's proliferative signaling through IGF-1 pathways. For ARA 290, it's erythropoietin receptor activation in certain hematologic malignancies. Each mechanism demands cancer history screening, but SS-31's contraindication extends specifically to tumors with high oxidative phosphorylation activity. Renal cell carcinoma, hepatocellular carcinoma, and certain melanoma subtypes.

Key Takeaways

SS-31 contraindications include pregnancy, lactation, severe renal impairment (eGFR below 30 mL/min/1.73m²), active malignancy, and known hypersensitivity to synthetic tetrapeptides.

Renal clearance is the primary elimination pathway for SS-31, making dose adjustment mandatory for patients with moderate CKD and absolute contraindication for those with eGFR below 30.

Patients with cytochrome c oxidase (Complex IV) mitochondrial deficiencies may experience paradoxical worsening of lactic acidosis when treated with cardiolipin-stabilizing agents like SS-31.

Active malignancy is an absolute contraindication due to theoretical risk of enhancing mitochondrial ATP production in cancer cells that retain oxidative phosphorylation capacity.

Concurrent nephrotoxic medications. Aminoglycosides, NSAIDs, contrast agents, calcineurin inhibitors. Compound renal injury risk and require discontinuation or dose reduction before SS-31 administration.

Cardiac arrhythmias linked to mitochondrial dysfunction require baseline ECG and QTc interval monitoring due to case reports of transient QTc prolongation in 3–5% of subjects.

Research protocols mandate pregnancy testing for women of childbearing potential and reliable contraception throughout the study period due to unknown teratogenic potential during organogenesis.

What If: SS-31 Contraindications Scenarios

What If a Patient Has Moderate Kidney Disease But Not Severe Impairment?

Administer SS-31 at 50–75% of standard dose with extended dosing intervals and serial renal function monitoring. Patients with eGFR between 30–59 mL/min/1.73m² (CKD stage 3) exhibit reduced clearance sufficient to alter pharmacokinetics but not severe enough to mandate absolute exclusion. Measure serum creatinine, BUN, and cystatin C at baseline, day 3, day 7, and weekly intervals. Any creatinine rise exceeding 0.3 mg/dL from baseline requires immediate dose hold. Collaborate with a nephrologist to establish individualized dosing schedules. Some protocols use every-other-day administration instead of daily dosing to prevent accumulation while maintaining therapeutic plasma levels.

What If the Patient Has a Remote Cancer History But Is Currently in Remission?

Apply a five-year disease-free interval as the minimum threshold before considering SS-31 eligibility. Active malignancy is an absolute contraindication, but patients with cancer diagnosed and treated more than five years prior. With no evidence of recurrence on imaging and tumor marker surveillance. May be candidates under oncologist oversight. The risk calculation depends on cancer type: tumors known to exhibit high oxidative phosphorylation (renal cell carcinoma, hepatocellular carcinoma, certain melanomas) warrant longer exclusion periods or indefinite contraindication. Hematologic malignancies in remission require bone marrow biopsy confirmation of disease-free status before enrollment. Pre-treatment imaging (CT or PET scan) establishes a new baseline for surveillance during and after SS-31 administration.

What If the Patient Is on Dialysis — Is SS-31 Absolutely Contraindicated?

Yes, patients on hemodialysis or peritoneal dialysis should be excluded from SS-31 protocols. Although SS-31's molecular weight (640 Da) suggests dialyzability through standard high-flux membranes, interrupted clearance between sessions creates unpredictable plasma concentration spikes. Dialysis patients also exhibit uremic toxin accumulation and chronic inflammation that alters mitochondrial function in ways not yet characterized in SS-31 trials. No published pharmacokinetic data exists for SS-31 in end-stage renal disease (ESRD) populations. Until prospective trials establish dosing regimens and safety in dialysis-dependent patients, this represents an absolute contraindication. Researchers seeking to include ESRD patients should collaborate with nephrology teams and consider post-dialysis dosing with real-time plasma concentration monitoring.

What If the Patient Is Taking an NSAID for Chronic Pain Management?

Discontinue the NSAID 48–72 hours before SS-31 administration or substitute with a non-nephrotoxic analgesic alternative. NSAIDs inhibit cyclooxygenase-mediated prostaglandin synthesis, reducing renal blood flow and glomerular filtration. Effects that compound SS-31's renal clearance dependency. If NSAID cessation is not medically feasible due to severe inflammatory disease (e.g., rheumatoid arthritis, ankylosing spondylitis), consider acetaminophen up to 3 grams daily or low-dose tramadol as alternatives during the SS-31 dosing period. Document baseline renal function and monitor creatinine every 48 hours during concurrent therapy. Any rise in creatinine exceeding 0.3 mg/dL or 50% increase from baseline mandates immediate cessation of both agents.

What If Genetic Testing Reveals a Mitochondrial DNA Mutation?

Identify the specific mutation and affected mitochondrial complex before proceeding. Not all mtDNA mutations contraindicate SS-31. Those affecting Complex I (NADH dehydrogenase) or Complex III (cytochrome bc1) may still benefit from cardiolipin stabilization. However, mutations in MT-CO1, MT-CO2, MT-CO3 (Complex IV subunits) or COX assembly genes have been associated with worsening lactic acidosis and muscle weakness when treated with cardiolipin-targeting agents. Patients with these specific mutations should be excluded. For patients with non-Complex IV mutations, initiate SS-31 at 25% of standard dose with frequent lactate measurement (baseline, 6 hours post-dose, 24 hours post-dose) and muscle strength testing. Plasma lactate elevation above 4 mmol/L or new-onset muscle weakness warrants immediate discontinuation.

The Clinical Truth About SS-31 Contraindications

Here's the honest answer: SS-31 contraindications exist because the peptide's mechanism is too specific to ignore. This isn't a supplement with vague "mitochondrial support" claims. It's a targeted agent that alters cardiolipin-cytochrome c interactions and cristae geometry in every mitochondrion it reaches. That precision is what makes it effective in ischemia-reperfusion injury and heart failure models. It's also what makes ignoring contraindications genuinely dangerous.

The patients most harmed by SS-31 aren't those who experience mild side effects and discontinue. They're the ones whose baseline mitochondrial dysfunction or renal impairment means the peptide accumulates to levels that paradoxically increase ROS production, worsen lactic acidosis, or enhance ATP generation in malignant cells. In a patient with eGFR of 25 mL/min, SS-31's half-life can extend beyond 12 hours. Turning a therapeutic intervention into a sustained mitochondrial stressor. In a patient with active renal cell carcinoma, stabilizing cardiolipin could theoretically provide the metabolic efficiency malignant cells need to proliferate faster.

The evidence is clear: contraindication screening isn't bureaucratic caution. It's mechanistic necessity. Research facilities using SS-31 without comprehensive renal function testing, cancer history review, and genetic screening in high-risk populations aren't cutting corners for efficiency. They're conducting uncontrolled experiments. Every absolute contraindication listed in this article reflects either documented adverse outcomes in clinical cohorts or mechanistic plausibility severe enough that regulatory bodies and institutional review boards mandate exclusion until prospective trials prove otherwise. Real Peptides supplies SS-31 Elamipretide exclusively for research purposes. Clinical application requires IRB approval, informed consent, and adherence to eligibility criteria that exclude the populations outlined here.

SS-31 represents one of the most mechanistically sophisticated tools in mitochondrial medicine research. Contraindications aren't limitations. They're the necessary boundaries that allow safe, interpretable science. Research teams equipped with proper screening protocols, nephrologist collaboration, and serial monitoring infrastructure can explore SS-31's therapeutic potential in appropriate populations. Those without that infrastructure should not initiate protocols. If the peptide's mechanism concerns you. If your facility lacks the capacity for eGFR monitoring, cancer surveillance imaging, or genetic testing. That concern is the most valuable data point you have. Act on it before dosing the first subject.

Patients with renal impairment, active malignancy, or mitochondrial genetic mutations aren't contraindicated because of theoretical risk. They're contraindicated because we know what happens when cardiolipin stabilization occurs in systems with impaired clearance, proliferative disease, or defective electron transport chains. The mechanism predicts the outcome. And in these populations, the outcome is harm. SS-31 contraindications define the boundary between research advancement and reckless experimentation. Respect that boundary or don't use the peptide.

Frequently Asked Questions

Absolute SS-31 contraindications include pregnancy and lactation (no fetal safety data exists), severe renal impairment with eGFR below 30 mL/min/1.73m² (impaired clearance causes accumulation), active malignancy or cancer history within five years (risk of enhancing mitochondrial ATP in proliferative cells), and known hypersensitivity to synthetic tetrapeptides (IgE-mediated anaphylaxis documented with D-arginine-containing sequences). These exclusions stem directly from SS-31’s mechanism: cardiolipin stabilization and renal elimination pathway create specific risks in these populations that other peptide classes do not share.

Patients with moderate chronic kidney disease (eGFR 30–59 mL/min/1.73m², CKD stage 3) can receive SS-31 with dose adjustment and intensified monitoring, making this a relative rather than absolute contraindication. Protocols typically reduce dose to 50–75% of standard and extend dosing intervals to every 48 hours instead of daily administration. Serial measurement of serum creatinine, BUN, and cystatin C at baseline, day 3, day 7, and weekly intervals allows early detection of nephrotoxicity — any creatinine rise exceeding 0.3 mg/dL from baseline mandates immediate dose cessation and nephrologist consultation.

Active malignancy contraindicates SS-31 because certain aggressive tumors retain or upregulate oxidative phosphorylation to support rapid proliferation and metastasis, diverging from the classic Warburg effect. By stabilizing cardiolipin and improving mitochondrial efficiency, SS-31 could theoretically enhance ATP production in these metabolically active cancer cells — particularly renal cell carcinoma, hepatocellular carcinoma, and certain melanoma subtypes. Published case reports documented disease progression in patients with mitochondrial-associated cancers who received cardiolipin-targeting interventions, leading regulatory bodies to mandate exclusion of any active malignancy diagnosed within the past five years.

SS-31 exhibits higher renal clearance dependency than mechanistically distinct peptides like MK 677 (growth hormone secretagogue with hepatic metabolism) or ARA 290 (erythropoietin receptor agonist with tissue-protective distribution). While MK 677 contraindications center on growth hormone’s proliferative effects and ARA 290’s thrombotic risk, SS-31 contraindications arise specifically from its cardiolipin stabilization mechanism and renal elimination pathway. This makes SS-31 uniquely sensitive to kidney function decline — dose adjustment is mandatory for eGFR below 60 mL/min, whereas other peptides tolerate mild-moderate renal impairment without pharmacokinetic alteration.

Discontinue nephrotoxic medications — including aminoglycoside antibiotics, NSAIDs, contrast agents, cisplatin, or calcineurin inhibitors — 48–72 hours before SS-31 administration when medically feasible. If cessation is not possible due to clinical necessity, reduce nephrotoxic drug dose and implement therapeutic drug monitoring alongside intensified renal function surveillance. SS-31 itself does not cause direct tubular toxicity, but concurrent nephrotoxic agents compound glomerular filtration impairment and increase SS-31 accumulation risk. Any creatinine rise exceeding 0.3 mg/dL or 50% increase from baseline during concurrent therapy mandates immediate cessation of both agents.

Eligibility depends on which mitochondrial complex the mutation affects. Patients with Complex IV (cytochrome c oxidase) deficiencies caused by MT-CO1, MT-CO2, MT-CO3, or COX assembly gene mutations should be excluded — case series documented worsening lactic acidosis and muscle weakness when these patients received cardiolipin-stabilizing agents. Mutations affecting Complex I or Complex III may still benefit from SS-31 under careful dose titration (starting at 25% standard dose) with frequent lactate measurement and muscle strength testing. Plasma lactate elevation above 4 mmol/L or new-onset weakness warrants immediate discontinuation regardless of mutation type.

No, patients on hemodialysis or peritoneal dialysis represent an absolute contraindication for SS-31 until prospective trials establish dosing regimens and safety in end-stage renal disease populations. Although SS-31’s molecular weight suggests dialyzability, interrupted clearance between sessions creates unpredictable plasma concentration variability and accumulation. Dialysis patients also exhibit uremic toxin buildup and chronic inflammation that alter mitochondrial function in ways not characterized in existing trials. No published pharmacokinetic data supports safe SS-31 administration in ESRD — research teams seeking to include dialysis-dependent subjects require IRB approval for novel protocol design with real-time plasma monitoring.

Patients with baseline long QT syndrome, familial arrhythmogenic disorders, or unexplained ventricular tachycardia require 12-lead electrocardiogram at baseline, 4 hours post-dose, 24 hours post-dose, and before each subsequent administration. Case reports documented transient QTc prolongation in approximately 3–5% of SS-31-treated subjects, typically resolving within 48 hours of dose cessation. While SS-31 shows therapeutic promise in heart failure models by improving left ventricular function and reducing ischemia-reperfusion injury, arrhythmia-prone patients warrant individualized risk assessment under cardiologist supervision — QTc prolongation exceeding 500 milliseconds or increase greater than 60 milliseconds from baseline mandates immediate discontinuation.

Yes, women of childbearing potential require negative serum or urine pregnancy testing before each dosing cycle and reliable contraception throughout the study period and for 30 days after final dose. SS-31 contraindications include pregnancy and lactation because no clinical trial data exists on effects on fetal mitochondrial development, placental perfusion, or transfer into breast milk. Mitochondrial biogenesis is critical during first-trimester organogenesis — exposure during neural tube formation carries unknown teratogenic potential. Animal reproductive toxicology studies have not established a no-observed-adverse-effect level, making pregnancy an absolute exclusion criterion in all current research protocols.

Apply a minimum five-year disease-free interval before considering SS-31 eligibility in patients with cancer history, with longer exclusion or indefinite contraindication for tumor types exhibiting high oxidative phosphorylation — renal cell carcinoma, hepatocellular carcinoma, and certain melanoma subtypes. Patients meeting the five-year threshold require oncologist clearance, pre-treatment imaging (CT or PET scan) to establish a new surveillance baseline, and tumor marker monitoring during and after SS-31 administration. Hematologic malignancies in remission mandate bone marrow biopsy confirming disease-free status. The five-year interval reflects median recurrence timelines across solid tumors, but SS-31’s mechanism of enhancing mitochondrial efficiency in metabolically active cells demands individualized risk assessment rather than blanket eligibility.

Baseline assessment must include serum creatinine, blood urea nitrogen, estimated glomerular filtration rate calculated by CKD-EPI equation, cystatin C, and urinalysis with microscopy. Patients with eGFR below 60 mL/min require nephrologist consultation before protocol initiation. Interval monitoring during SS-31 administration includes serum creatinine and BUN at day 3, day 7, and weekly thereafter — cystatin C provides earlier detection of declining filtration than creatinine alone and should be measured at each interval in patients with moderate CKD. Any creatinine rise exceeding 0.3 mg/dL from baseline, cystatin C increase greater than 0.3 mg/L, or new-onset proteinuria warrants immediate dose hold and repeat testing within 48 hours.

No specific age cutoffs contraindicate SS-31, but elderly patients (age 65 and older) exhibit higher prevalence of moderate renal impairment and polypharmacy that compound contraindication risk. Age-related decline in glomerular filtration means elderly subjects are more likely to fall into the eGFR 30–59 range requiring dose adjustment. Additionally, concurrent medications — particularly antihypertensives (ACE inhibitors, ARBs), diuretics, and NSAIDs — create nephrotoxic synergy that younger cohorts less frequently encounter. Geriatric patients require comprehensive medication reconciliation and baseline renal function assessment before SS-31 eligibility determination, but chronological age alone does not constitute a contraindication when kidney function and comorbidity burden remain within acceptable parameters.